Latest studies
- RecruitingPHASE3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
This study is testing a new medicine, volrustomig, for people with a type of head and neck cancer that hasn't spread and wasn't removed by surgery. It aims to see if volrustomig helps prevent the cancer from coming back after standard treatment like chemotherapy and radiotherapy.
Locally Advanced Head and Neck Squamous Cell CarcinomaVietnam - Active not recruitingPHASE3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
This study is testing a new medicine, ianalumab, for adults with active lupus nephritis. It compares ianalumab given every 4 or 12 weeks to a dummy medicine, alongside standard treatments, to see if it's safe and effective.
Lupus NephritisVietnam - RecruitingPHASE3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
This study is looking into a new medication called AZD0780. It aims to see if this medicine can lower the risk of serious heart problems like heart attacks or strokes in people who have already had them, or in those at high risk of having one for the first time.
Cardiovascular DiseaseVietnam - Active not recruitingPHASE3
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
This study is looking into a new combination treatment for a type of breast cancer called triple-negative breast cancer (TNBC) that has spread or is advanced. It combines a new drug, Capivasertib, with a common chemotherapy, Paclitaxel, to see if it works better than just Paclitaxel alone.
Triple Negative Breast NeoplasmsVietnam - RecruitingPHASE2
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
This study looks at a new treatment called obe-cel for severe lupus affecting the kidneys (lupus nephritis). It's for people aged 12-65 whose current treatments haven't worked. The aim is to see if obe-cel can make their kidney lupus go into remission.
Lupus NephritisVietnam - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat advanced lung cancer (squamous non-small cell lung cancer) that has spread. It compares two different drug combinations, including a new medicine called rilvegostomig, to see if they can help patients live longer and improve their quality of life.
Non-small Cell Lung CancerVietnam - RecruitingPHASE3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
This study looks at a new medicine, Baxdrostat, combined with an existing one, Dapagliflozin, for people with long-term kidney disease and high blood pressure. It aims to see if this combination can help protect the kidneys and heart better than Dapagliflozin alone.
Chronic Kidney Disease and HypertensionVietnam - Active not recruitingPHASE3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
This study looks at a new combination treatment for advanced breast cancer that's hormone-positive and HER2-negative. It combines a new drug called capivasertib with existing treatments to see if it works better at slowing down the cancer's growth.
Locally Advanced (Inoperable) or Metastatic Breast CancerVietnam - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
This study is looking at new ways to treat advanced non-small cell lung cancer (a type of lung cancer) that has spread. It compares an experimental drug, rilvegostomig, with a standard drug, pembrolizumab, both given with chemotherapy, to see which works better and is safer.
Non-squamous Non-small Cell Lung CancerVietnam - RecruitingPHASE3
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
This study looks into a new drug, Datopotamab Deruxtecan (Dato-DXd), for advanced lung cancer. It compares Dato-DXd to a standard treatment, Docetaxel, in patients whose cancer has responded to previous treatments and has a specific marker called TROP2.
Non-small Cell Lung Cancer (NSCLC)Vietnam - Active not recruitingPHASE3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
This study is testing a new medicine, inclisiran, to see if it can prevent serious heart problems like heart attacks and strokes in people who are at high risk but haven't had one before. They are comparing it to a dummy medicine.
Primary Prevention of Atherosclerotic Cardiovascular DiseaseVietnam - Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This study, called POSEIDON, is testing new drug combinations for people with a type of lung cancer called non-small cell lung cancer (NSCLC). It's comparing usual chemotherapy with combinations of two new drugs, durvalumab and tremelimumab, to see if they work better.
Non Small Cell Lung Cancer NSCLCVietnam - RecruitingPHASE3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study looks into a new treatment for adults with heart failure. It combines two medicines, vicadrostat and empagliflozin, to see if they can improve heart health in people with a specific type of heart failure. Participants take tablets daily and are closely monitored.
Heart FailureVietnam - Active not recruitingPHASE3
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
This study looks at new drug combinations for bladder cancer that has spread into the muscle. It compares them to standard treatment for people who can't take or don't want cisplatin chemotherapy before surgery to remove their bladder. The aim is to find more effective and safe options.
Muscle Invasive Bladder CancerVietnam - RecruitingPHASE3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
This study is testing a new drug, camizestrant, for early breast cancer that's hormone-sensitive. We want to see if it works better than standard hormone therapy in reducing the risk of cancer coming back, for people who have already had initial treatment.
Breast Cancer, Early Breast CancerVietnam - Active not recruitingPHASE3
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
This study looks at the long-term safety and effects of the medicine onasemnogene abeparvovec (OAV101) for Spinal Muscular Atrophy (SMA). It follows people who previously took part in an OAV101 trial for five years to see how they are doing.
Spinal Muscular Atrophy (SMA)Vietnam - Recruiting
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
The RIETE study is building a large database of information from patients with blood clots (venous thromboembolism). It helps doctors better understand and treat patients, especially those with other health problems, to improve care and understand what medicine works best for different groups.
Venous ThromboembolismVietnam - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
This study looks for better ways to treat early-stage, high-risk breast cancer. It tests a new targeted therapy, sacituzumab tirumotecan, with other standard treatments to see if it reduces cancer and helps people live longer without the cancer returning.
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast NeoplasmsVietnam - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesVietnam - Active not recruitingPHASE3
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
This study looks at combining a drug called osimertinib with chemotherapy for a type of lung cancer. It wants to see if this combination works better than osimertinib alone for patients with a specific genetic change in their cancer, hoping to delay the cancer getting worse.
Non-Small Cell Lung CancerVietnam - RecruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
This study is looking at a new combination of treatments for advanced lung cancer. It compares giving two drugs together (sacituzumab tirumotecan and pembrolizumab) against giving pembrolizumab on its own, to see if the combination helps people live longer.
Non-small Cell Lung Cancer (NSCLC)Vietnam - RecruitingPHASE3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
This study is testing new combinations of medicines for advanced liver cancer (hepatocellular carcinoma) that can't be cured with surgery. It compares different drug blends to a common treatment to see which works best and is safest.
Hepatocellular CarcinomaVietnam - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesVietnam - RecruitingPHASE3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
This study is testing a new medicine, nerandomilast, for people with systemic sclerosis. It aims to see if the medicine can improve symptoms and slow the disease. Adults with systemic sclerosis might be able to join this study.
Systemic SclerosisVietnam - RecruitingPHASE3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study investigates if a new drug, vicadrostat, combined with empagliflozin, can help adults with heart failure and a weakened heart pump. Participants will take study medications for up to 3.5 years, alongside their usual care.
Heart FailureVietnam - RecruitingPHASE3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
This study looks at new drug combinations for stomach or food pipe cancer that has spread. It compares an experimental treatment with standard care, aiming to find better ways to treat patients whose cancer has specific features.
Gastric CancerGastroesophageal Junction CancerVietnam - Active not recruitingPHASE3
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
This study is testing a new medicine, remibrutinib, for adults with a type of chronic (long-lasting) hives that hasn't improved with usual antihistamine tablets. It will check if the medicine works, is safe, and is well-tolerated. Some people will receive a dummy treatment (placebo) at first.
Chronic Inducible UrticariaVietnam - Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This study looks at new treatments (Durvalumab, Tremelimumab) for a type of lung cancer, Small Cell Lung Cancer, after initial strong treatment. It aims to see if these drugs can stop the cancer from coming back.
Small Cell Lung CancerVietnam - RecruitingPHASE4
Asciminib Roll-over Study
This study is for people who have already been taking a medicine called asciminib (or similar drugs) in a Novartis study for a type of blood cancer called CML. It allows them to keep taking the medicine if their doctor thinks it's still helping them.
Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveVietnam - Enrolling by invitationPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
This study is for cancer patients who have already been in another durvalumab drug trial and are still benefiting from the treatment. It lets them continue receiving the drug to see if it keeps helping them.
CancerVietnam - Active not recruitingPHASE3
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
This study looks at new ways to treat a type of lung cancer before surgery. We're testing a drug called osimertinib, either alone or with chemotherapy, against chemotherapy by itself. The goal is to see if these new treatments can help more people with resectable non-small cell lung cancer.
Non-Small Cell Lung CancerVietnam - Recruiting
Pompe Disease Registry Protocol
This registry tracks people with Pompe disease globally. It helps us understand the condition better, how it changes over time, and the effects of treatments. The goal is to improve care for everyone with Pompe disease.
Glycogen Storage Disease Type IIPompe DiseaseVietnam - RecruitingPHASE3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
This study looks at new treatments for heart failure and kidney problems. Researchers are testing two different doses of a new drug combination against an existing medication to see if they can improve heart health and reduce hospital stays.
Heart Failure and Impaired Kidney FunctionVietnam - RecruitingPHASE3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
This study looks at new drug combinations for stomach (gastric) or food pipe (GEJ) cancer that has a specific marker called HER2. It compares different treatment mixes to see which works best and is safest for advanced cancer.
HER2-positive Gastric CancerGastroesophageal Junction AdenocarcinomaVietnam - Active not recruitingPHASE3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
This study looks at new treatments (Durvalumab and Domvanalimab) for advanced lung cancer (Stage III NSCLC) after standard radiation and chemotherapy. It aims to see if combining these medicines helps patients whose cancer hasn't worsened after initial treatment.
Non-Small Cell Lung CancerVietnam - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
This study looks at a new drug, claseprubart, for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It aims to see if the drug helps people with CIDP and if it's safe. Some participants will receive the drug, and others a dummy treatment.
Chronic Inflammatory Demyelinating PolyneuropathyVietnam - RecruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
This study is testing a new medicine, Elecoglipron, for adults with type 2 diabetes and kidney problems. It compares Elecoglipron to a dummy pill (placebo) to see if it's safe and effective when taken with other usual diabetes medicines, including dapagliflozin.
Type 2 Diabetes MellitusType 2 Diabetes With Chronic Kidney DiseaseVietnam - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
This study compares a new medicine, Sacituzumab Tirumotecan, with standard chemotherapy for advanced lung cancer. It’s for people whose cancer has specific genetic changes and has already been treated. We're looking to see if the new medicine helps people live longer and keeps their cancer from growing for longer.
Non-small Cell Lung Cancer (NSCLC)Vietnam - RecruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
This study looks at new ways to treat type 2 diabetes by testing two medicines, Elecoglipron and Dapagliflozin, both on their own and together. Researchers want to see how well they work and if they are safe for adults with type 2 diabetes.
Type 2 Diabetes MellitusVietnam - RecruitingPHASE3
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
This study looks at a new drug called anifrolumab for adults with muscle conditions like polymyositis or dermatomyositis. Researchers want to see if it's safe and helps improve symptoms when added to their usual treatment.
Polymyositis, DermatomyositisVietnam - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
Breast CancerVietnam - Enrolling by invitationPHASE2, PHASE3
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
This study looks at the long-term safety and effects of a medicine called sibeprenlimab for people with a kidney condition called IgA Nephropathy. It's for those who have already been part of earlier studies with this medicine.
Immunoglobulin A NephropathyVietnam - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Vietnam - Active not recruitingPHASE3
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
This study looks at a new drug, AZD0780, for people with heart disease or who are at risk of it, and who have high 'bad' cholesterol (LDL-C). We want to see if AZD0780 safely lowers this cholesterol.
Cardiovascular DiseaseVietnam - Active not recruitingPHASE3
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
This study is testing a new medicine called sibeprenlimab for a kidney disease called IgA nephropathy (IgAN). It aims to see if the medicine can reduce protein in the urine and protect kidney function over time, compared to a dummy medicine.
Immunoglobulin A NephropathyVietnam - Active not recruitingPHASE3
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
This study looks at a new, higher dose of macitentan (75mg) for people with pulmonary arterial hypertension (PAH). Researchers want to see if this dose is better than the current 10mg dose at preventing serious health problems or death related to PAH.
Pulmonary Arterial HypertensionVietnam - RecruitingPHASE3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
This study looks at how two medicines, Baxdrostat and dapagliflozin, might help people with heart failure. We're testing if this combination can reduce hospital stays for heart failure or prevent death from heart problems in people with type 2 diabetes and high blood pressure.
Heart FailureVietnam - RecruitingPHASE3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
This study looks at a new drug, patritumab deruxtecan, for a certain type of advanced breast cancer. It aims to see if this new treatment helps people live longer or stops cancer from growing compared to standard treatments like chemotherapy.
Breast NeoplasmsVietnam - Active not recruitingPHASE3
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
This study is testing a new combination of treatments for adults with advanced lung cancer (NSCLC) that hasn't spread to the brain or spine and doesn't have certain genetic changes. It compares this new treatment to a standard one, hoping it works better.
NSCLCVietnam - RecruitingPHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This study looks at new treatments for a type of breast cancer called triple-negative. It compares a new drug, Dato-DXd, sometimes with Durvalumab, against standard chemotherapy with Pembrolizumab for patients whose cancer has come back locally or spread.
Breast CancerVietnam